Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. (NTRA) – Form 4 filing
CFO Michael Burkes Brophy reported a routine set of transactions tied to RSU vesting and a previously adopted Rule 10b5-1 plan.
- RSU conversion: On 22 Jul 2025, 1,250 restricted stock units vested and were converted to common shares (Code M).
- Share sales: The executive sold 2,170 shares across four trades on 22-24 Jul at weighted-average prices of $139.20-$141.28 to cover tax-withholding and liquidity needs.
- Net change: Beneficial ownership fell by 1,250 shares, leaving Brophy with 70,494 common shares (<≈1.8% reduction) and 1,250 unvested RSUs.
- Plan status: All dispositions were executed under a 10b5-1 plan adopted 14 Jun 2024, limiting discretionary timing.
No other corporate events or material financial information are disclosed in this filing.